Provided by Tiger Fintech (Singapore) Pte. Ltd.

MoonLake Immunotherapeutics

46.88
-1.9500-3.99%
Post-market: 46.880.00000.00%18:52 EDT
Volume:881.42K
Turnover:42.17M
Market Cap:2.98B
PE:-20.35
High:49.81
Open:49.25
Low:46.73
Close:48.83
Loading ...

MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating

TIPRANKS
·
13 May

MoonLake Immunotherapeutics Q1 Loss Widens

MT Newswires Live
·
13 May

MoonLake Q1 EPS $(0.63) Beats $(0.74) Estimate

Benzinga
·
13 May

MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
13 May

MoonLake Immunotherapeutics: Extending Expected Cash Runway Into 2028

THOMSON REUTERS
·
13 May

MoonLake Immunotherapeutics Reports Steady R&D Expenses and Increased General Administrative Costs in Q1 2025 Financial Results

Reuters
·
13 May

MoonLake Immunotherapeutics Q1 EPS USD -0.63

THOMSON REUTERS
·
13 May

MoonLake Immunotherap Price Target Maintained With a $66.00/Share by Needham

Dow Jones
·
30 Apr

Is MoonLake Immunotherapeutics (MLTX) Among the Best Guru Stocks to Buy According to Wall Street Analysts?

Insider Monkey
·
24 Apr

MoonLake Obtains $500 Million Facility From Hercules Capital

MT Newswires Live
·
03 Apr

BRIEF-Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates

Reuters
·
03 Apr

MoonLake Immunotherapeutics secures up to $500M in non-dilutive financing

TIPRANKS
·
03 Apr

MoonLake Secures up to $500 Million in Non-Dilutive Financing From Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

THOMSON REUTERS
·
03 Apr

MoonLake Immunotherap Initiated at Outperform by RBC Capital

Dow Jones
·
18 Mar

RBC Capital Initiates a Buy Rating on MoonLake Immunotherapeutics (MLTX)

TIPRANKS
·
18 Mar

RBC Initiates MoonLake Immunotherapeutics at Outperform, Speculative Risk With $17 Price Target

MT Newswires Live
·
18 Mar

MoonLake Immunotherapeutics: Promising Prospects for Sonelokimab in Inflammatory Diseases

TIPRANKS
·
12 Mar

MoonLake Immunotherap Is Maintained at Buy by Needham

Dow Jones
·
27 Feb

Moonlake Immunotherapeutics Faces Hurdles in Commercializing SLK Despite Potential Approvals

TIPRANKS
·
27 Feb

Buy Rating for MoonLake Immunotherapeutics Driven by Promising Clinical Programs and Market Potential

TIPRANKS
·
27 Feb